Regulatory Clearance obtained to Initiate Ph 1 Trial for PQ203 in the U.S. and Canada; FDA Fast Track Designation Granted
“This is a major step forward for ProteinQure and for the field of rationally designed peptide therapeutics,” said Dave Garman, VP Translation and Development at ProteinQure. “The Fast Track designation reflects the FDA’s recognition of the promise PQ203 holds for cancer patients, and we are thrilled to move swiftly into the clinic across North America.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.